Navigation Links
Women are treated less frequently than men with statins, aspirin and beta-blockers
Date:3/4/2008

CHICAGO Women and men experience a similar prevalence of adverse drug reactions in the treatment of coronary artery disease; however, women are significantly less likely than their male counterparts to be treated with statins, aspirin, and beta-blockers according to a new study by researchers at Rush University Medical Center. The study is published in the March issue of the journal Gender Medicine.

Developments in disease recognition and novel treatment strategies have led to a significant decline in overall cardiovascular death rate among men, but these dramatic improvements have not been observed in women, said Dr. Jonathan R. Enriquez, lead author of the study and resident internal medicine physician at Rush. This may be related to underutilization of medical therapies such as aspirin, -blockers, ACE inhibitors or statins.

In association with Dr. Annabelle Volgman and the Rush Heart Center for Women, the study involved 304 consecutive patients with coronary artery disease at the outpatient cardiology clinic at Rush. A retrospective observational analysis was performed to determine the usage and adverse reactions reported from aspirin, -blockers, angiotensin-converting-enzyme (ACE) inhibitors or statins. Baseline clinical characteristics were also determined to identify the independent association of gender on usage of standard medical coronary artery disease treatments.

The study found that only 78.1 percent of women were treated with statins compared to 90.8 percent of men. After adjustment for clinical characteristics, men were also found to be six times more likely to receive aspirin and beta-blockers. No significant difference was noted between genders in the prevalence of adverse drug reactions

The physicians perception of either anticipated adverse drug reactions or less severe disease may be influencing their decision to not prescribe these medications for women, said Enriquez. We encourage further studies to identify the cause of this disparity, so that care for women with coronary artery disease may be optimized.

Coronary artery disease is the leading-cause of death among women in the United States and annually since 1984 the number of cardiovascular-related deaths in women has exceeded that of men. Women may not only suffer from decreased survival with coronary artery disease, but may also experience a worse quality of life than men.

Given the findings of this study and other studies documenting the underutilization of current medical therapies in women, we must consider potential solutions to improve care of all patients during the outpatient visit, said Enriquez.


'/>"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Painful Sex in Women: Studies Show High Prevalence, but New Hope
2. New Survey Shows 90 Percent of Women Do Not Fully Understand the Calories They Eat
3. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
4. Women Health Care Executives Names Genomic Health President Kimberly Popovits as Woman of the Year
5. Pelvic Floor Disorders Affect 1 in 3 Women
6. Kaiser Permanente Study Shows One-Third of Women Have Overactive Bladder, Incontinence or Other Pelvic Floor Disorders
7. When couples face the diagnosis of cancer, women carry a larger emotional burden than men
8. Study examines how men and women view marital and parental time pressures
9. Breast cancer death rates among black women not decreasing across all states
10. Specialized Care Essential for Women With Congenital Heart Disease Undergoing Pregnancy
11. Healthcare Businesswomens Association Names Genentechs Leonard Kanavy, Vice President, Commercial Operations as the 2008 Honorable Mentor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: